19 June 2013
Keywords: lilly, generex, end, diabetes, deal, biotechnology, eli
Article | 02 June 2003
Generex Biotechnology and Eli Lilly have decided to terminate their development and licensing agreement for buccal formulations of insulin.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 June 2003
26 May 2003
18 June 2013
© 2013 thepharmaletter.com